KNIGHT THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.73 CAD | +0.70% |
|
+0.17% | +10.40% |
| 22/03 | Knight Therapeutics Price Target Raised to $7 at RBC | MT |
| 21/03 | Knight Therapeutics Reports Fourth Quarter Results | MT |
| Sales 2024 * | 345M 252M 21.02B | Sales 2025 * | 354M 259M 21.61B | Capitalization | 580M 424M 35.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 3M 2.19M 183M | Net income 2025 * | 2M 1.46M 122M | EV / Sales 2024 * | 1.68 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 1.64 x |
| P/E ratio 2024 * |
63.7
x | P/E ratio 2025 * |
58.8
x | Employees | 725 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 53.56% |
More Fundamentals
* Assessed data
More news
Latest transcript on Knight Therapeutics Inc.
More recommendations
More press releases
More news
| 1 day | +0.70% | ||
| 1 week | +0.17% | ||
| Current month | +8.11% | ||
| 1 month | +5.52% | ||
| 3 months | +2.32% | ||
| 6 months | +29.35% | ||
| Current year | +10.40% |
1 week
5.56
5.88
1 month
5.235.95
Current year
5.135.95
1 year
4.355.95
3 years
4.286.20
5 years
4.288.88
10 years
4.2811.03
| Managers | Title | Age | Since |
|---|---|---|---|
Samira Sakhia
CEO | Chief Executive Officer | 55 | 01/13/01 |
Jonathan Goodman
FOU | Founder | 56 | 01/13/01 |
Arvind Utchanah
DFI | Director of Finance/CFO | - | 20/16/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Gale
BRD | Director/Board Member | 74 | 06/14/06 |
Jonathan Goodman
FOU | Founder | 56 | 01/13/01 |
Robert N. Lande
BRD | Director/Board Member | 61 | 01/13/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.19% | 11 M€ | -.--% | ||
| 0.01% | 773 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 5.73 | +0.70% | 41,264 |
| 25/24/25 | 5.69 | -0.52% | 59,340 |
| 24/24/24 | 5.72 | -1.72% | 22,021 |
| 23/24/23 | 5.82 | +0.52% | 26,122 |
| 22/24/22 | 5.79 | +1.22% | 40,198 |
Delayed Quote Toronto S.E., April 27, 2024 at 01:30 am IST
More quotes
Knight Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company's principal business activity includes developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invested in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The Company's portfolio consists of pharmaceutical products with molecules and includes both in-licensed products, such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome as well as products owned (or partially owned) by it, such as Exelon and Impavido.
Sector
Pharmaceuticals
Calendar
08/05/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.73
CAD
Average target price
6.729
CAD
Spread / Average Target
+17.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.40% | 424M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- GUD Stock
